title: Heterogeneity in preferences for smoking cessation.
abstract: Promoting cessation is a cornerstone of tobacco control efforts by public-health agencies. Economic information to support cessation programs has generally emphasized cost-effectiveness or the impact of cigarette pricing and smoking restrictions on quit rates. In contrast, this study provides empirical estimates of smoker preferences for increased efficacy and other attributes of smoking cessation therapies (SCTs). Choice data were collected through a national survey of Canadian smokers. We find systematic preference heterogeneity for therapy types and SCT attributes between light and heavy smokers, as well as random heterogeneity using random parameters logit models. Preference heterogeneity is greatest between length of use and types of SCTs. We estimate that light smokers would be willing to pay nearly $500 ($CAN) to increase success rates to 40% with the comparable figure for heavy smokers being near $300 ($CAN). Results from this study can be used to inform research and development for smoking cessation products and programs and suggest important areas of future inquiry regarding heterogeneity of smoker preferences and preferences for other health programs.
authors.affiliation: Industrial Economics, Inc., Cambridge, MA, USA. rwp@indecon.com
authors.forename: Robert W
authors.initials: RW
authors.lastname: Paterson
authors.forename: Kevin J
authors.initials: KJ
authors.lastname: Boyle
authors.forename: Christopher F
authors.initials: CF
authors.lastname: Parmeter
authors.forename: James E
authors.initials: JE
authors.lastname: Neumann
authors.forename: Paul
authors.initials: P
authors.lastname: De Civita
mesh_terms: D000328:Adult; D016642:Bupropion / Q000191:economics / Q000627:therapeutic use; D018765:Dopamine Uptake Inhibitors / Q000191:economics / Q000627:therapeutic use; D005260:Female; D005731:Ganglionic Stimulants / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D016013:Likelihood Functions; D008297:Male; D008954:Models, Biological; D009538:Nicotine / Q000191:economics / Q000627:therapeutic use; D017060:Patient Satisfaction / Q000191:economics*; D016540:Smoking Cessation / Q000191:economics* / Q000379:methods / Q000523:psychology*; D014029:Tobacco Use Disorder / Q000188:drug therapy*
chemical_list: D018765:Dopamine Uptake Inhibitors; D005731:Ganglionic Stimulants; D016642:Bupropion; D009538:Nicotine